• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on MSCI Inc. (NYSE: MSCI)

    1/17/24 9:00:00 AM ET
    $MSCI
    $RPRX
    $SWI
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MSCI alert in real time by email

    NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management

    Provides Evidence That Each of MSCI's Four Business Segments is Under Pressure, Resulting in Client Retention Challenges

    Expresses Concern That MSCI Uses Aggressive Accounting and Financial Reporting to Place Greater Emphasis on Adjusted EPS While Cash Flow Stagnates and the Dividend Growth Rate Plunges

    Believes MSCI's $949 Million Acquisition of Real Capital Analytics Should be Evaluated for Impairment After Client Losses and Rising Competition

    Observes That MSCI Exhibits a Pattern of Opaque Deal-Making with People and Entities Related to Morgan Stanley and Questions if They are in the Best Interest of Shareholders

    Believes That MSCI – Known for its Environmental, Social and Governance Ratings – Has its Own Social and Governance Deficiencies That Must be Improved

    Sees 55% to 65% Long-Term Downside Risk to MSCI's Share Price and Believes MSCI's Stock Should Be Underweighted Relative to the S&P 500

    Spruce Point Capital Management, LLC ("Spruce Point" or "we" or "us"), a New York-based investment management firm that focuses on forensic research and short-selling, today issued a detailed report entitled "Indexing The Short Case Against MSCI" that outlines why we believe shares of MSCI Inc. (NYSE:MSCI) ("MSCI" or the "Company") face up to 55% to 65% long-term downside risk, or $190.00 – $244.00 per share. Download or view the report by visiting www.SprucePointCap.com for additional information and exclusive updates.

    ***

    Spruce Point Report Overview

    MSCI, founded as Morgan Stanley Capital International, is a provider of decision support tools and solutions for the global investment community. The Company has four reporting segments: Index, Analytics, ESG and Climate, and All-Other Private Assets, which includes real estate analytics and the recently acquired Burgiss Group. MSCI's clients include asset owners (pensions, endowments, etc.), asset managers, financial intermediaries, wealth managers, real estate professionals and corporations. MSCI services 6,500 clients in over 95 countries. We believe each of MSCI's four segments is under pressure and that the Company is using a variety of aggressive financial reporting and accounting methods, along with expensive acquisitions, in an attempt to position itself for a changing investment landscape.

    The concerns we outline in our report include:

    • MSCI's core index business is under pressure, client Retention Rates are declining, executive leadership is being replaced, and reputational risks are rising. MSCI's core index business (58% of revenue) is no longer the driving force of innovation it once was. Through our research, we found that the Company understates the growing competition it faces from exchanges like Qontigo (owned by Deutsche Börse) and Nasdaq, which are increasing pressure on MSCI as they expand with new software and data solutions. We find that MSCI's Index segment Retention Rate, a measure of future revenue, has declined year-over-year in the past four consecutive quarters.



      In addition, MSCI also faces additional strain from its clients – such as BlackRock – that are under pressures of their own. For instance, approximately 10% and 17% of MSCI's total and Index segment revenue currently comes from BlackRock, which is embracing self-indexing, which reduces its need for MSCI's services. On top of that, BlackRock's U.S. market share of iShares ETFs is in perpetual decline, with analysts expecting Vanguard to soon become the new leader. As a result, it is no surprise that MSCI's fees linked to ETFs have also been in perpetual decline. In November, MSCI replaced its Head of Index, while BlackRock's Head of iShares departed last week. The combination of these events cast greater uncertainty over the relationship. On top of that, we believe MSCI's recent purchase of The Burgiss Group ("Burgiss") now puts it in greater competition with BlackRock, which could further pressure the relationship and fees.



      Other macro factors working against MSCI are higher interest rates and a strong dollar. Higher rates have caused total assets of AUM benchmarked to MSCI indices to decline almost double digits since 2021. In Q3'23, MSCI reported a decline in total clients and it has recently expanded risk factors that explain why client activity decreases. Absent punitive price increases, we estimate new recurring sales are down 40% in YTD'23. To win in "growth areas" such as thematic ETFs, MSCI's CEO recently referenced itself as having to turn into "a giant equity research shop." We believe the cost and complexity of transforming a large company such as MSCI with pronounced innovation challenges will be too difficult to surmount.



      Beyond competition and macro factors, MSCI's index franchise has also exposed itself to reputational risk in pursuit of fees by promoting Chinese indexed ETFs. As an example, Congress recently questioned MSCI's role in diverting capital towards Chinese companies included within the index that are possibly engaging in human rights violations.



    • MSCI's Analytics segment is also under pressure, anchored by increasingly commoditized solutions. The Analytics segment is ~26% of MSCI's revenue and ~18% of Adjusted EBITDA. As one former MSCI employee with 18 years of experience developing models said, "It's less about brain power – lots of physics PhDs in quant land – and more about the difficult and unglamorous job of sourcing, curating, managing and QA'ing data and the 24/7 operations to ensure updates are there every day, on time, for every asset class, for every model, for every client." Spruce Point believes artificial intelligence will automate and improve data management to further reduce competitive barriers and fees.



      In 2016, MSCI stated its intention to accelerate Analytics revenue growth rate from low to mid-single digits to the upper single digits over the long term. Seven years later, the growth rate has increased modestly to the 6% range (aided recently by punitive fee increases) but has averaged just 4.5% over the time period. Most of the segment was built with acquisitions dating 15-20 years ago and are still anchored by RiskMetrics and Barra Solutions. Not surprisingly, in a recent interview, an industry expert opined that MSCI's models are becoming commoditized. MSCI's results reinforce the reality that its Analytics segment is under increased pressures. For example, Spruce Point observes that MSCI recently experienced year-over-year declines in its organic sales growth, Adjusted EBITDA margin and client Retention Rate metrics. Client Retention Rate has fallen in three of the last four quarters while Adjusted EBITDA margin growth is declining after a period of strong expansion. Now, MSCI is referencing higher compensation costs across cost of revenue, selling and marketing and G&A, offset by lower R&D compensation expense after a period of cost capitalization. Our interpretation is that MSCI is likely experiencing wage pressures by retaining employees who may be looking to depart while customers churn.



    • Despite having been MSCI's recent growth driver, the Company's ESG and Climate segment is now beginning to struggle. Since 2020, MSCI's ESG and Climate Solutions business has been a growth engine with run rate revenue increasing from $138 million to $297 million and margins expanding from 20.5% to 34.8%. However, we believe the growth spurt is ending not only because of ESG pushback, regulatory uncertainty, and ESG's market underperformance but also because of MSCI-specific issues that have resulted in notable client retention challenges.



      In 2023, MSCI changed the way in which it describes the competitive advantages of its ESG and Climate business from having a "Unique Track Record" to simply having a "Long Track Record." To say that something is unique means that it is one of a kind or unlike anything else – but to say something has a long track record does not have the same notability. We view this modification in choice of words, along with MSCI's expanding disclosure of competitors such as Bloomberg and Moody's in its recent 10-K, as an indicator that its ESG and Climate business is coming under increased pressure. In addition, MSCI also added a pop-up box on its rating page to be used in sales lead generation before providing its public ratings. When we interviewed a former MSCI executive, we were told, "ESG competition is definitely increasing, especially Bloomberg. MSCI was one of the first, but that doesn't mean competitors aren't going to eat away at it. As early as 2023, people were leaving the ESG team. To grow, you have to have consistent sales. They were under target and didn't hit their goals. That business line was struggling." Lastly, we observe that MSCI is increasing its cost capitalization of development expense, which has the obvious effect of flattering margins.



    • The Private Assets segment, formed by the acquisitions of Real Capital Analytics ("RCA") in 2021 and The Burgiss Group ("Burgiss") in 2023, is fraught with continued challenges. MSCI's acquisition of RCA for $949 million was richly valued at approximately 13x and 48x run-rate revenue and EBITDA, respectively. We believe the RCA acquisition was littered with challenges and shows MSCI's propensity for aggressive revenue accounting. MSCI quickly marked down total clients from 2,000 to 1,600 after the acquisition but continued to claim that it had a high retention rate and that revenue should be considered recurring. MSCI and analysts talked up RCA's mid-to-high teens revenue growth and high and improving renewal rates. However, within a year after the acquisition, the evidence points to substantially lower revenue growth and MSCI stopped reporting RCA's Run-Rate revenue – a suspicious coincidence. A former MSCI employee commented, "The RCA deal was not the best or easiest transition. It was pretty disorganized. It was like a dumpster fire. There were a lot of mismanaged accounts. I don't think they did enough due diligence, like on their run rate, and what they are producing. There were a lot of outdated or accounts that weren't updated." Segment organic growth recently went negative while segment retention rate is negative on both a QoQ and YoY basis.



      In 2023, MSCI acquired the 66.4% of The Burgiss Group it didn't own at an implied 10x and 68x revenue and EBITDA, respectively. Spruce Point believes that at best Burgiss was breakeven and at worst it was losing money and it has struggled to grow its client base in the past four years. We have also identified evidence of weak accounting and/or financial controls as suggested by MSCI electing to report Burgiss' results on a three-month lag. Lastly, Burgiss competes with eFront, a company owned by BlackRock, which raises the risk of greater friction with its largest customer.



    • MSCI has exhibited an alarming pattern of nepotism-like acquisitions and alliances with Morgan Stanley and MSCI-related alums. MSCI was formerly Morgan Stanley Capital International, so there is no hiding the fact that its roots originated at Morgan Stanley. MSCI IPO'ed in 2007, and Morgan Stanley was its lead underwriter.



      Unsurprisingly, we find that MSCI has recently engaged in a suspicious pattern of acquisitions and alliances that benefit Morgan Stanley and well-known MSCI alums. Overall, we question whether these deals are in the best interest of MSCI shareholders or are being done simply to benefit the former colleagues in the circle of MSCI Chairman and CEO Henry Fernandez. We refer to this as nepotism-like dealing and we find many recent examples.
         

    (1)

    In 2021, Mr. Fernandez became Lead Independent Director of Royalty Pharma plc (NYSE:RPRX), which receives fees from MSCI for advice on science-based thematic ETFs. Morgan Stanley is also a top shareholder of RPRX. Mr. Fernandez's son became employed at RPRX around the time of his father's appointment.

         

     

         

    (2)

    In 2022, MSCI struck an alliance with Menai Financial Group, a company in the digital asset space intended to provide MSCI advice, with undisclosed deal terms. Menai was founded by Zoe Cruz, former co-President of Morgan Stanley.

         

     

         

    (3)

    When it comes to the recent Burgiss transaction in 2023, Jay McNamara was President of Burgiss and was formerly an Executive Committee member at MSCI. MSCI hasn't disclosed how much Mr. McNamara personally benefited from the transaction, which, as we pointed out, was at a rich valuation.

         

     

         

    (4)

    Lastly, in December 2023, MSCI acquired Fabric, a wealth technology platform for an undisclosed amount. Our research suggests that Fabric had limited headcount and web traffic growth. Fabric's co-founder was formerly Morgan Stanley's first Chief Risk Officer.

    • MSCI is shifting attention to Adjusted EPS while cash flow and dividend growth struggles and aggressive accounting decisions flatter revenue and costs. MSCI ceased providing margin guidance and dismissed margins as not meaningful while putting greater emphasis on Adjusted EPS. In 2022, MSCI changed management's long-term compensation targets to cumulative Adjusted EPS and revenue despite not providing investors with guidance on either metric. We believe MSCI uses a variety of dubious adjustments to bolster its Adjusted EPS.



      By our estimate, Adjusted EPS was -28% and -13% below MSCI's reported results in 2021 and 2022, respectively. MSCI's revenue in recent quarters has been flattered with non-recurring revenue, some of which is related to prior periods. On the cost side, MSCI's segment reporting gives management the potential for wide latitude to manipulate margins to its benefit. We observe that it can allocate costs by segment using different methods without incurring "arm's length" charges. Lastly, MSCI appears to be making greater use of capitalized development costs that are added to the balance sheet, amortized to the income statement and conveniently ignored as non-cash add-backs. MSCI should disclose how much costs are being capitalized per segment and the exact effect on margins. As of its last financial update, MSCI has not been able to increase cash flow guidance even as operating costs rise and after tapping the revolver for additional liquidity to complete the Burgiss acquisition (despite enough cash on hand and cash flow). Moreover, MSCI's dividend growth has averaged 27.9% from inception in 2014 through 2023 but its recent increase was 10.4%, the lowest growth rate ever. We believe management may be signaling cash flow growth challenges ahead with these actions.



    • In the context of our findings about aggressive accounting decisions and lapses in acquisition due diligence, we have grave concerns about Board, audit, and accounting oversight at MSCI. We are alarmed to see that MSCI's Chief Accounting Officer (CAO) resigned on August 18, 2023. As of this report, MSCI has not named a successor to the CAO role and it does not have a Global Controller, which should be a significant red flag for investors. In addition, we question the fitness of MSCI's Director Catherine Kinney who has served on the Board since 2009. Ms. Kinney has not only been involved with SolarWinds (NYSE:SWI) since its IPO, but most concerning, she served as the Chair of the Nominating and Governance Committee which was responsible for firm-wide risk management. She was also a member of the Audit Committee. Spruce Point finds it alarming that the SEC recently charged SolarWinds with fraud for internal control failures during Ms. Kinney's directorship. Also of concern is the fact that MSCI claims its Audit Committee "Financial Expert" is Robert Ashe. Mr. Ashe has primarily served in operational and business management roles during his career with a brief stint as a public company CFO of Cognos over 20 years ago. While he was CEO of Cognos, the Company delayed its 10-K/Q as the SEC reviewed its revenue recognition policies. He has a CPA in Canada, but MSCI reports in U.S. GAAP. If the weakness with MSCI's Board and accounting oversight is not evident enough, we also find evidence that MSCI's PwC Audit Engagement Partner is not a financial services specialist. Her other audit clients are primarily chemical and shipping companies, and her LinkedIn biography references the title "Industrial Products Assurance Partner."



    • The bottom line is that an investment in MSCI presents a poor risk/reward for investors, given the Company's high expectations, rich valuation and apparent struggles. Analysts are bullish on MSCI, however, the average sell-side consensus price target is $554/share, representing just 2.6% upside potential. Spruce Point believes the current sell-side promoters need to refresh their thinking about MSCI and the sustainability of its growth and margins, especially in "faster growth" segment areas in ESG and Climate and Private Assets. We believe it is easy to dismiss much of the bull case narrative with some simple channel checks, a close forensic review of MSCI's financials and by speaking with former employees. Specifically, we believe analysts and investors need to rethink the sustainability of MSCI's high client retention in a changing competitive landscape and its capital allocation policies. We believe management is showing poor discipline with acquisitions, while deploying too much capital to share repurchases with its stock trading at an industry-high multiple of 17x and 29x 2024E revenue and Adjusted EBITDA. Investors would be better served with a higher dividend rather than allowing management to essentially buy its way toward handsome long-term bonuses tied to Adjusted EPS. MSCI's leverage is now at a decade high at approximately 3x Net Debt / EBITDA which we believe is at the worst time as client Retention Rates decline. By conducting a realistic sum-of-parts valuation of MSCI's business segments, we estimate 55% - 65% ($190.00 – $244.00 per share) downside risk and expect MSCI to underperform the S&P 500 and its own relevant benchmark indices.

    ***

    Please note that the items summarized in this press release are expanded upon and supported with data, public filings and records, and images in Spruce Point's full report. As a reminder, our full report, along with its investment disclaimers, can be downloaded and viewed at www.SprucePointCap.com.

    As disclosed, Spruce Point and/or its clients have a short position in MSCI Inc. and owns derivative securities that stand to net benefit if its share price falls.

    About Spruce Point

    Spruce Point Capital Management, LLC is a forensic fundamentally-oriented investment manager that focuses on short-selling, value and special situation investment opportunities.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240117565436/en/

    Get the next $MSCI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MSCI
    $RPRX
    $SWI

    CompanyDatePrice TargetRatingAnalyst
    MSCI Inc.
    $MSCI
    7/25/2025$650.00Mkt Perform → Outperform
    Raymond James
    Royalty Pharma plc
    $RPRX
    5/16/2025$51.00Overweight
    Morgan Stanley
    MSCI Inc.
    $MSCI
    4/10/2025$585.00Neutral
    BofA Securities
    SolarWinds Corporation
    $SWI
    2/7/2025Outperform → Neutral
    Wedbush
    SolarWinds Corporation
    $SWI
    12/19/2024$20.00Outperform
    Wedbush
    MSCI Inc.
    $MSCI
    12/18/2024$617.00 → $723.00Neutral → Buy
    Goldman
    MSCI Inc.
    $MSCI
    12/12/2024Peer Perform → Outperform
    Wolfe Research
    MSCI Inc.
    $MSCI
    10/9/2024$680.00Neutral → Buy
    Redburn Atlantic
    More analyst ratings

    $MSCI
    $RPRX
    $SWI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MSCI upgraded by Raymond James with a new price target

    Raymond James upgraded MSCI from Mkt Perform to Outperform and set a new price target of $650.00

    7/25/25 8:52:35 AM ET
    $MSCI
    Real Estate

    Morgan Stanley initiated coverage on Royalty Pharma with a new price target

    Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

    5/16/25 8:05:49 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on MSCI with a new price target

    BofA Securities resumed coverage of MSCI with a rating of Neutral and set a new price target of $585.00

    4/10/25 12:43:08 PM ET
    $MSCI
    Real Estate

    $MSCI
    $RPRX
    $SWI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Norden Gregory sold $1,213,749 worth of Class A Ordinary Shares (33,500 units at $36.23) and converted options into 144,660 units of Class A Ordinary Shares, increasing direct ownership by 133% to 194,848 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/11/25 4:35:58 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO, Chairman of the Board Legorreta Pablo G. was granted 21,901 units of Class A Ordinary Shares, increasing direct ownership by 2% to 904,396 units (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/8/25 5:00:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Coyne Terrance P. was granted 3,696 units of Class A Ordinary Shares (SEC Form 4)

    4 - Royalty Pharma plc (0001802768) (Issuer)

    8/8/25 4:58:17 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSCI
    $RPRX
    $SWI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Fernandez Henry A bought $6,731,599 worth of shares (12,400 units at $542.87), increasing direct ownership by 0.79% to 1,279,951 units (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    7/28/25 4:30:18 PM ET
    $MSCI
    Real Estate

    Chairman and CEO Fernandez Henry A bought $3,044,902 worth of shares (5,300 units at $574.51), increasing direct ownership by 0.42% to 1,269,951 units (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    2/25/25 6:27:41 AM ET
    $MSCI
    Real Estate

    Chairman and CEO Fernandez Henry A bought $1,777,119 worth of shares (2,900 units at $612.80) (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    12/9/24 6:55:51 AM ET
    $MSCI
    Real Estate

    $MSCI
    $RPRX
    $SWI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MSCI to Participate in Barclays Global Financial Services Conference; Publishes Investor Presentation

    MSCI Inc. ("MSCI" or the "Company") (NYSE:MSCI), a global connector of the financial ecosystem helping clients navigate risk and opportunity through data, models and research-based insights, announced today that Chief Financial Officer Andrew Wiechmann will participate in a fireside chat at the Barclays Global Financial Services Conference on Monday, September 8, 2025 at 12:00 PM Eastern Time. A live webcast and replay of these events will be available on the events and presentations section of MSCI's Investor Relations homepage, https://ir.msci.com/events-and-presentations. Separately, the Company also published an investor presentation for investors on its Investor Relations homepage,

    8/18/25 11:42:00 AM ET
    $MSCI
    Real Estate

    Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. "We are tremendously grateful for Henry's contributions to Royalty Pharma over the past five years," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "His experience as a seasoned chief executive of a public company together with his exceptional business acumen has been invaluable to Royalty Pharma duri

    8/13/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MSCI Forges Strategic Collaboration with PNC Bank to Expand Personalized Wealth Management

    MSCI Inc. (NYSE:MSCI) and PNC Bank have entered into a strategic collaboration to provide financial advisors of PNC with access to MSCI Wealth Manager – a fully integrated digital platform with robust analytics, portfolio management tools, institutional-grade research and solutions to help advisors create more personalized experiences for end-investors. From high-net-worth and emerging-affluent individuals to large, sophisticated institutional investors, asset and wealth managers are increasingly asked to create customized portfolios that reflect their end-clients' unique financial goals, risk tolerance and values. MSCI Wealth Manager was designed to support advisors' efforts to provide t

    8/13/25 8:00:00 AM ET
    $MSCI
    Real Estate

    $MSCI
    $RPRX
    $SWI
    SEC Filings

    View All

    MSCI Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - MSCI Inc. (0001408198) (Filer)

    8/20/25 4:19:34 PM ET
    $MSCI
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plc

    SCHEDULE 13G/A - Royalty Pharma plc (0001802768) (Subject)

    8/14/25 8:30:21 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Royalty Pharma plc

    8-K - Royalty Pharma plc (0001802768) (Filer)

    8/13/25 4:33:18 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSCI
    $RPRX
    $SWI
    Financials

    Live finance-specific insights

    View All

    Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. "We are tremendously grateful for Henry's contributions to Royalty Pharma over the past five years," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "His experience as a seasoned chief executive of a public company together with his exceptional business acumen has been invaluable to Royalty Pharma duri

    8/13/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Reports Second Quarter 2025 Results

    Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $364 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) --  Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% growth in Portfolio Receipts, and raised our full year guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Additionally, we

    8/6/25 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MSCI Reports Financial Results for Second Quarter and Six Months 2025

    MSCI Inc. ("MSCI" or the "Company") (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, today announced its financial results for the three months ended June 30, 2025 ("second quarter 2025") and six months ended June 30, 2025 ("six months 2025"). Financial and Operational Highlights for Second Quarter 2025 (Note: Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 ("second quarter 2024") and Run Rate percentage changes are relative to June 30, 2024). Operating revenues of $772.7 million, up 9.1%; Organic operating revenue growth of 8.3% Recurring subscription revenu

    7/22/25 6:45:00 AM ET
    $MSCI
    Real Estate

    $MSCI
    $RPRX
    $SWI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $MSCI
    $RPRX
    $SWI
    Leadership Updates

    Live Leadership Updates

    View All

    Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    11/8/24 3:15:49 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

    SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

    7/29/24 4:30:11 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MSCI Inc. (Amendment)

    SC 13G/A - MSCI Inc. (0001408198) (Subject)

    2/13/24 5:09:39 PM ET
    $MSCI
    Real Estate

    Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

    Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global pr

    7/17/25 8:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enact Holdings Set to Join S&P SmallCap 600

    NEW YORK, April 9, 2025 /PRNewswire/ -- Enact Holdings Inc. (NASD: ACT) will replace SolarWinds Corp. (NYSE:SWI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, April 16. Turn/River Capital is acquiring SolarWinds in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 16, 2025 S&P SmallCap 600 Addition Enact Holdings ACT Financials April 16, 2025 S&P SmallCap 600 Deletion SolarWinds SWI Information Technology For more information about S&P Dow Jones Indices, please vi

    4/9/25 5:42:00 PM ET
    $ACT
    $SPGI
    $SWI
    Specialty Insurers
    Finance
    Finance: Consumer Services
    Computer Software: Prepackaged Software

    Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

    4/8/25 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care